Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat

European Journal of Pharmacology

Volumn 379, Issue 2-3, 1999, Pages 125-133

  Connor, Thomas J ^a   Kelliher, Padraig ^a   Harkin, Andrew ^a   Kelly, John P ^a   Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Antidepressant; Depression; Forced swim test; Noradrenaline; Reboxetine; Serotonin; Stress

Indexed keywords

NEUROTRANSMITTER; REBOXETINE;

AMYGDALOID NUCLEUS; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEFECATION; DEPRESSION; DOPAMINERGIC ACTIVITY; FRONTAL CORTEX; IMMOBILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC TRANSMISSION; STRESS; SWIMMING;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CORTICOSTERONE; DEFECATION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMOBILIZATION; MALE; MORPHOLINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; STRESS; SWIMMING;

EID: 0032747406     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00492-6     Document Type: Article

References (54)

1. Alonso G., Szafarczyk A., Balmfrezol M., Assenmacher I. Immunocytochemical evidence for stimulatory control by the ventral noradrenergic bundle of parvocellular neurons of the paraventricular nucleus secreting corticotropin-releasing hormone and vassopressin in rats. Brain Res. 397:1986;297-300.
2. Anisman H., Zacharko R. Depression: the predisposing influence of stress. Behav. Brain Sci. 5:1982;89-137.
3. Araki H., Kawashima K., Uchiyama Y., Aihara H. Involvement of amygdaloid catecholaminergic mechanism in suppressive effects of desipramine and imipramine on duration of immobility in rats forced to swim. Eur. J. Pharmacol. 113:1985;313-318.
4. Baraban J.M., Aghajanian G.K. Suppression of serotonergic neuronal firing by alpha-adrenoceptor antagonists: evidence against GABA mediation. Eur. J. Pharmacol. 66:1980;287-294.
5. Baraban J.M., Aghajanian G.K. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology. 19:1980;355-363.
6. Benkert O., Grunder G., Wetzel H., Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in patients with major depression and melancholia. J. Psychiatr. Res. 30:1996;441-452.
7. Bidzinska E.J. Stress factors in affective diseases. Br. J. Psychiatry. 144:1984;161-166.
8. Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci. Biobehav. Rev. 19:1995;377-395.
9. Connor T.J., Kelly J.P., Leonard B.E. Forced swim test-induced neurochemical, endocrine and immune changes in the rat. Pharmacol. Biochem. Behav. 58:1997;961-968.
10. Connor T.J., Kelliher P., Shen Y., Harkin A., Kelly J.P., Leonard B.E. Differential effects of chronic antidepressant treatments on behavioural, neurochemical and endocrine changes following forced swim test exposure. Eur. Neuropsychopharmacol. 8:1998;S194. Suppl. 2.
11. Curet O., De Montigney C., Blier P. Effect of desipramine and amphetamine on noradrenergic neurotransmission: Electrophysiological studies in the rat brain. Eur. J. Pharmacol. 221:1992;59-70.
12. Davis M., Hitchcock J.M., Bowers M.B., Berridge C.W., Melia K.R., Roth R.H. Stress-induced activation of prefrontal cortex dopamine turnover: blockade by lesions of the amygdala. Brain Res. 664:1994;207-210.
13. Delbende C., Delarue C., Lefebvre H., Tranchand Bunel D., Szafarczyk A., Mocaer E., Kamoun A., Jegou S., Vaudry H. Glucocorticoids, transmitters and stress. Br. J. Psychiatry. 160:1992;24-34.
14. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology. 121:1995;66-72.
15. Detke M.J., Johnson J., Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp. Clin. Psychopharmacol. 5:1997;107-112.
16. Dinan T.G. Glucocorticoids and the genesis of depressive illness - a psychobiological model. Br. J. Psychiatry. 164:1994;365-371.
17. Duncan G.E., Breese G.R., Criswell H., Stumpf W.E., Mueller R.A., Covey J.B. Effects of antidepressant drugs injected into the amygdala on behavioral responses of rats in the forced swim test. J. Pharmacol. Exp. Ther. 238:1986;758-762.
18. Dunn A.J. Stress-related changes in cerebral catecholamine and indoleamine metabolism: lack of effect of adrenalectomy and corticosterone. J. Neurochem. 51:1988;406-412.
19. Galzin A.M., Moret C., Langer S.Z. Evidence that exogenous but not endogenous norepinephrine activates the presynaptic alpha-2 adrenoceptors on serotonergic nerve endings in the rat hypothalamus. J. Pharmacol. Exp. Ther. 228:1984;725-732.
20. Ge J., Barnes N.M., Costall B., Naylor R.J. Effect of aversive stimulation on 5-hydroxytryptamine and dopamine metabolism in the rat brain. Pharmacol. Biochem. Behav. 58:1997;775-783.
21. Grealy M., O'Donnell J.M. Secretion of growth hormone elicited by intravenous desipramine in the conscious, unrestrained rat. Br. J. Pharmacol. 102:1991;369-372.
22. Grenhoff J., Svensson T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol. 233:1993;79-84.
23. Guelfi J.D., White C., Hackett D., Gaichoux J.Y., Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiatry. 56:1995;450-458.
24. Harkin A., Kelly J.P., McNamara M., Connor T.J., Dredge K., Redmond A., Leonard B.E. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur. J. Pharmacol. 364:1999;123-132.
25. Hertel P., Lindblom N., Nomikos G.G., Svensson T.H. Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;815-834.
26. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17:1996;187-205.
27. Inoue T., Koyama T., Yamashita I. Effect of conditioned fear stress on serotonin metabolism in rat brain. Pharmacol. Biochem. Behav. 44:1993;371-374.
28. Inoue T., Tsuchiya K., Koyama T. Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain. Pharmacol. Biochem. Behav. 49:1994;911-920.
29. Jordan S., Kramer G.L., Zukas P.K., Petty F. Previous swim stress increases in vivo biogenic amine response to swim stress. Neurochem. Res. 19:1994;1521-1525.
30. Kawahara H., Yoshida M., Yokoo H., Nishi M., Tanaka M. Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci. Lett. 162:1993;81-84.
31. Kelliher P., Harkin A.J., Connor T.J., Sanchez C., Kelly J.P., Leonard B.E. Circadian alterations in the rat forced swim test. Behav. Pharmacol. 9:1998;A49. Suppl. 1.
32. Kelliher P., Connor T.J., Kelly J.P., Leonard B.E. Novel correlates of re-uptake inhibitor activity in the rat forced swim test. J. Psychopharmacol. 12:1998;. Suppl. A12.
33. Leonard B.E. Noradrenaline in basic models of depression. Eur. Neuropsychopharmacol. 7:1997;11-16. Suppl. 1.
34. Lopez-Ibor J.J., Guefli J.D., Pletan Y., Tournoux A., Prost J.F. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int. Clin. Psychopharmacol. 11:1996;41-46. Suppl. 4.
35. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309:1996;1-11.
36. Melloni P., Carniel G., Della Torre A., Bonsignori A., Buonamici M., Pozzi O., Ricciardi S., Rossi S.C. Potential antidepressant agents. a aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur. J. Med. Chem. 19:1984;235-242.
37. Nelson, J.C., 1998. Synergistic effects of serotonergic and noradrenergic antidepressants in combination. In: Briley, M., Montgomery, S. (Eds.), Antidepressant Therapy at the Dawn of the Third Millennium. Martin Dunitz, United Kingdom, 297-305.
38. 2-Adrenoceptors and depression. J. Psychopharmacol. 10:1996;s35-s42.
39. Potter W.Z. Adrenoceptors and serotonin receptor function. Relevance to antidepressant mechanisms of action. J. Clin. Psychiatry. 57:1996;4-8.
40. Petty F., Jordan S., Kramer G.L., Zukas P.K., Wu J. Benzodiazepine prevention of swim stress-induced sensitization of cortical biogenic amines: an in vivo microdialysis study. Neurochem. Res. 22:1997;1101-1104.
41. Popov N., Pohle W., Rosler V., Matthies H. Regionale verteilung von gamma-aminobuttersaure, glutaminsaure, asparaginsaure, dopamin, noradrenalin und serotonin in rattenhirn. Acta Med. Biol. Germ. 18:1967;695-702.
42. Porsolt R.D., Bertin A., Blavet M., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47:1978;379-391.
43. Redmond A.M., Leonard B.E. An evaluation of the role of the noradrenergic system in the neurobiology of depression: a review. Hum. Psychopharmacol. 12:1997;407-430.
44. Riva M., Brunello N., Rosecalli A.C., Galimberti R., Carfragna N. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J. Drug Dev. 1:1989;243-252.
45. Roth, R.H., Wolf, M.E., Deutch, A.Y., 1987. Neurochemistry of midbrain dopamine systems. In: Meltzer, H.Y. (Ed.), Psychopharmacology: the Third Generation of Progress. Raven Press, New York, 81-94.
46. Schweizer E., Weise C., Clary C., Fox I., Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J. Clin. Psychopharmacol. 11:1991;233-236.
47. Seyfried C.A., Adams G., Greve T. An automated direct-injection HPLC method for the electrochemical/fluorometric quantitation of monoamines and related compounds optimized for screening of large numbers of animals. Biomed. Chromotogr. 1:1986;78-88.
48. Stahl, S.M., 1997. Psychopharmacology of Antidepressants. Martin Dunitz, United Kingdom, 25-28.
49. Svensson, T.H., Linner, L., Arborelius, L., 1998. Electrophysiology of brain noradrenaline neurons and the mode of action of antidepressant drugs. In: Briley, M., Montgomery, S. (Eds.), Antidepressant Therapy at the Dawn of the Third Millennium. Martin Dunitz, United Kingdom, 19-35.
50. Trendelenburg A.U., Trendelenburg M., Starke K., Limberger N. Release-inhibiting alpha 2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with alpha 2-autoreceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 349:1994;25-33.
51. Valentino R.J., Curtis A.L., Parris D.G., Wehby R.G. Antidepressant actions on brain noradrenergic neurons. J. Pharmacol. Exp. Ther. 253:1991;833-840.
52. Willner P. Animal models of depression: An overview. Pharmacol. Ther. 45:1990;425-455.
53. Willner, P., 1995. Dopaminergic mechanisms in depression and mania. In: Bloom, F.E., Kupfer, D.J. (Eds.), Psychopharmacology: the Fourth Generation of Progress. Raven Press, New York, 921-931.
54. Wong, E.H.F., Graveel, C.R., Smith, M.W., 1997. Pharmacological selectivity of reboxetine: A selective noradrenaline reuptake inhibitor (NRI). Am. Coll. Neuropsychopharmacol., Meeting Abstract, Hawaii, December, 1997.